GlassScriptPhysician profile
Deborah R Baum
NPI 1215919733
$4,102.12
in general payments reported to CMS, 2019-2025
20 companies · $3,515 in 2025
The $3,515 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $31.44 · 2021: $7.50 · 2022: $53.16 · 2023: $16.05 · 2024: $183 · 2025: $3,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $621 · Travel and Lodging: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $620.73 |
| Travel and Lodging | $593.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,135.40 | 2025 | |
| Glaxosmithkline, LLC. | $210.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $110.32 | 2019-2025 | Uptravi |
| Ceribell, INC. | $95.00 | 2025 | Pocket Eeg Device |
| Astrazeneca Pharmaceuticals LP | $92.93 | 2020-2025 | Fasenra, Tezspire |
| Boston Scientific Corporation | $69.21 | 2022-2023 | Bodyguardian |
| Sunovion Pharmaceuticals INC. | $52.42 | 2019-2020 | |
| Grifols USA, LLC | $46.21 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $38.46 | 2025 | |
| Amgen INC. | $31.94 | 2024-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $30.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.53 | 2024 | Ofev |
| Genzyme Corporation | $27.34 | 2024 | |
| Genentech USA, INC. | $27.29 | 2019 | |
| Mylan Specialty L.P. | $24.27 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.80 | 2024 | Glassia |
| Viatris Specialty LLC | $19.78 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $17.68 | 2024 | Dupixent |
| Philips North America LLC | $11.50 | 2019 | |
| United Therapeutics Corporation | $7.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.